Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nabiximols

An herbal preparation containing a defined quantity of specific cannabinoids formulated for oromucosal spray administration with potential analgesic activity. Nabiximols contains a standardized extract of tetrahydrocannabinol (THC), the non-psychoactive cannabinoid cannabidiol (CBD), other minor cannabinoids, flavonoids, and terpenes from two cannabis plant varieties. Cannabinoids interact with G protein-coupled cannabinoid 1 (CB1) receptors in the central nervous system, resulting in analgesic, euphoric, and anticonvulsive effects.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:cannabidiol mixture with tetrahydrocannabinol
cannabis-based oromucosal spray GW-1000-02
THC and CBD mixture
US brand name:Sativex
Foreign brand name:Sativex
Code name:GW-1000
GW-1000-02
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search